News Search Results
Mar 13, 2025, 05:00 ET Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality
With over 23 years of global expertise, Caliber continues to transform pharmaceutical and biotechnology companies with GxP Quality solutions across Quality Control, Quality Assurance, Manufacturing, and Data and Insights. These solutions help companies
More news about: Caliber Technologies
Mar 13, 2025, 04:00 ET Pioneering plant microbiome research: Julia Vorholt receives 2025 Novonesis Biotechnology Prize from the Novo Nordisk Foundation
properties of individual microbes – an essential step toward developing biotechnology solutions, including tailored microbial treatments that naturally suppress harmful microbes. Receiving the 2025 Novonesis Biotechnology Prize not only honours Vorholt's work but also highlights its potential
More news about: Novo Nordisk Foundation
Mar 12, 2025, 20:21 ET Cal Poly Pomona's Singelyn Graduate School of Business and Western University of Health Sciences Announce Innovative PharmD-MBA Pathway Program
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Mar 12, 2025, 19:30 ET STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Mar 12, 2025, 17:31 ET ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
(taletrectinib/AB-106/IBI-344) (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku), Zidesamtinib (NVL-520) (Nuvalent), ANS03 (Avistone Biotechnology), Zanidatamab (Jazz Pharmaceuticals), PT-112 (Promontory Therapeutics), and others. In December 2024,
More news about: DelveInsight Business Research, LLP
Mar 12, 2025, 17:08 ET Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Mar 12, 2025, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 12, 2025, 12:55 ET INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 12, 2025, 12:30 ET VITAMIN ANGELS APPOINTS GLOBAL HEALTH LEADER ANA CÉSPEDES AS CHIEF EXECUTIVE OFFICER
spearheading key initiatives in operational excellence and strategic growth. Prior to IAVI, Céspedes held senior leadership positions in pharmaceutical, biotechnology and strategic consulting sectors, including Lilly, Arthur Andersen, Serono and Merck KGaA, Darmstadt, Germany,
More news about: Vitamin Angels
Mar 12, 2025, 11:53 ET Urolithin A Market Grows Strongly with Rising Demand for Anti-Aging and Health Supplements | Valuates Reports
populations age and prioritize longevity-focused solutions, demand for Urolithin A supplements and therapeutics surges. Future advancements in biotechnology and personalized medicine will likely further elevate the market, securing Urolithin A's position as a crucial component in the evolving health
More news about: Valuates Reports
Mar 12, 2025, 10:30 ET Urinary Incontinence Devices Market worth US$7.97 billion by 2030 with 14.5% CAGR | MarketsandMarkets™
Investments at the levels that J&J makes over years guarantee a constant stream of innovation within the medical devices, pharmaceuticals, and biotechnology industries. These initiatives not only streamline its market approach but also ensure that it addresses landscape shifts in patient care with advanced
More news about: MarketsandMarkets
Mar 12, 2025, 10:08 ET PranaX Appoints Phillip Maderia as CEO to Lead Exosome Innovation
solidifying its role as a global leader in next-generation wellness. About PranaX CorporationPranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell-derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs through evidence-based
More news about: PranaX
Mar 12, 2025, 10:01 ET Clinical Trial Services Market worth US$101.86 billion by 2030 with 8.9% CAGR | MarketsandMarkets™
in the clinical trial service market offering services such as clinical development, patient access solutions, and consulting to pharmaceutical, biotechnology organizations, and medical device companies. The company's service portfolio includes comprehensive Phase I through IV clinical trial management,
More news about: MarketsandMarkets
Mar 12, 2025, 09:05 ET Shiru and GreenLab Partner to Scale Sustainable Protein Production Through Novel Corn-Based Expression System
ProteinDiscovery.ai for more. About GreenLabGreenLab's mission is to green industry through next-generation plant biotechnology. With GreenLab's platform, a cornfield is transformed into a factory of the future. GreenLab delivers on biotech's promise of next-generation proteins,
More news about: Shiru, Inc.
Mar 12, 2025, 08:47 ET GBI Biomanufacturing Announces Sven Lee as New Board Member
here to watch a short segment from our SME Series on Biologics Tech Transfer Process at GBI! About GBI Biomanufacturing (formerly Goodwin Biotechnology, Inc.) GBI is a premier Contract Development and Manufacturing Organization (CDMO) specializing in
More news about: GBI Biomanufacturing
Mar 12, 2025, 07:45 ET QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative
More news about: QurAlis
Mar 12, 2025, 06:18 ET Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results and a Cash Dividend
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.
Mar 12, 2025, 06:00 ET SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST
diagnostic service providers globally to bring this test to market and increase patient access. About SkylineDx SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Mar 12, 2025, 05:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Mar 12, 2025, 05:30 ET Turacoz Group Leads the Future of Evidence Synthesis With AI-Powered Living Systematic Reviews at World Evidence, Pricing and Access (EPA) Congress, Europe 2025
complex healthcare landscapes, demonstrating the value and impact of medical interventions. Committed to innovation, Turacoz empowers pharmaceutical, biotechnology, and healthcare stakeholders to make data-driven decisions that enhance patient outcomes, improve healthcare efficiencies, and optimize market access
More news about: Turacoz Healthcare BV
Mar 12, 2025, 05:30 ET Turacoz Group Leads the Future of Evidence Synthesis With AI-Powered Living Systematic Reviews at World Evidence, Pricing and Access (EPA) Congress, Europe 2025
complex healthcare landscapes, demonstrating the value and impact of medical interventions. Committed to innovation, Turacoz empowers pharmaceutical, biotechnology, and healthcare stakeholders to make data-driven decisions that enhance patient outcomes, improve healthcare efficiencies, and optimize market access
More news about: Turacoz Healthcare BV
Mar 12, 2025, 05:00 ET Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
"Pierre Fabre Laboratories are excited to enter into this agreement with RedRidge, which confirms our commitment to collaborate with innovative biotechnology companies. This partnership will allow us to capitalize on RedRidge's cutting-edge expertise in biparatopic antibody drug discovery to deliver high
More news about: Pierre Fabre Laboratories
Mar 12, 2025, 05:00 ET Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
"Pierre Fabre Laboratories are excited to enter into this agreement with RedRidge, which confirms our commitment to collaborate with innovative biotechnology companies. This partnership will allow us to capitalize on RedRidge's cutting-edge expertise in biparatopic antibody drug discovery to deliver high
More news about: Pierre Fabre Laboratories
Mar 12, 2025, 00:41 ET Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
www.harbourbiomed.com. About Élancé Therapeutics Élancé Therapeutics is a biotechnology company developing next-generation biologics for obesity treatment. Incubated by Harbour BioMed, Élancé Therapeutics leverages advanced bispecific
More news about: Harbour BioMed
Mar 11, 2025, 22:50 ET Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
us on Facebook, Twitter, Instagram and Snapchat (Society4Science). About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists,
More news about: Society for Science